CEGID
3.6.2021 08:02:05 CEST | Business Wire | Press release
Cegid, a leading provider of business management software solutions, and KKR, a leading global investment firm and one of the world’s leading technology and software investors, today announced that KKR will acquire a minority stake in the company at an Enterprise Value of €5.5 Billion. Silver Lake, a global leader in technology investing, will remain the majority shareholder and is committed to continuing to support Cegid’s growth strategy driven by the management team over the several coming years, in partnership with KKR and existing shareholder AltaOne.
Founded in 1983 and headquartered in Lyon, France, Cegid is a leading provider of enterprise software, offering functional (HCM, Finance and Tax), as well as vertical (CPA & SMB, Retail) cloud-based solutions. Cegid has been a SaaS pioneer and is today a European leader in providing cloud-based solutions since inception in 2004. Cegid provides cloud-based solutions to over 350,000 companies and 4.5 million users across the globe. Since Silver Lake’s investment in 2016, the company has extended its market leadership and experienced strong double-digit revenue and earnings growth, driven by focusing on SaaS solutions, as well as robust investments in next-generation cloud products and value-enhancing acquisitions.
Pascal Houillon, CEO of Cegid, said: “We are very proud of what we have built over the years and the high growth we have achieved. We have meaningfully expanded Cegid’s market reach geographically, as well as broadened our product portfolio and the range of customers we serve today, who have been trusting the Cegid teams and our expanded capabilities. We have developed a strong suite of best-in-class cloud products across all of our six business segments, continuously improved customer service and extended our offering through strategic acquisitions to grow existing markets and enter new verticals. We are looking forward to continuing the close and trusted partnership we have formed with Silver Lake, who have supported us on our value creation path with their deep software expertise and will carry on doing so over the years. As we continue to invest in world-class, useful and innovative cloud-based solutions, we are thrilled to welcome KKR as a new shareholder. We are convinced that their experience and support will be highly valuable in the next stage of the Cegid journey alongside our existing investors at the service of our clients’ business goals today and in the future.”
Christian Lucas, Co-Head of Silver Lake EMEA, said: “Cegid has developed an outstanding software platform that provides a full range of best-in-class and mission-critical business management solutions across a wide variety of verticals and customer groups. Its focus on cloud-based solutions, as well as its customer-centric approach, have propelled a strong growth trajectory. It continues to be a great pleasure to partner with Pascal and the entire Cegid management team since our investment. We look forward to supporting Cegid’s continued development as a European cloud champion as the majority shareholder for years to come and are delighted to build on the newly formed partnership with KKR as a basis for our continued engagement. We are convinced that KKR will be able to contribute a wealth of relevant expertise on this path and welcome them as new investors.”
Jean-Pierre Saad, Head of EMEA Technology at KKR, and Jérôme Nommé, Head of France at KKR, said: “We are excited to be part of Cegid’s journey going forward. We have followed the company for many years and have been impressed by the growth that Pascal and his team have achieved, transforming Cegid into a pan-European software leader. Today’s investment reflects our continued strategic focus on investing in leading European software businesses and on backing French tech champions in their growth journeys. We look forward to partnering with Cegid’s management team, Silver Lake and AltaOne to accelerate further Cegid’s next phase of growth.”
KKR is making its investment through its Core Investments strategy, which represents capital targeting longer-term opportunities.
The transaction is anticipated to close by the end of the third quarter subject to customary conditions and regulatory approvals. Further terms of the investment are not being disclosed at this time.
About Cegid
Cegid is a leading provider of cloud business management solutions for finance (ERP, cash management, tax), payroll & talent management, CPAs and retail professionals. With a proven track record in cloud management solutions, Cegid provides long term commitment to customers and helps digitalize businesses, from small to large businesses, from private to public sector. Cegid combines a proactive and pragmatic approach of business with expertise in new technologies and a unique understanding of regulations. In a rapidly changing world, Cegid makes more possible and helps customers unleash their potential thanks to innovative and purposeful business solutions.
Cegid has 3,000 employees and markets its solutions in 75 countries. In 2020, Cegid recorded a turnover of €498 million. Pascal Houillon has been the CEO since March 2017.
For more information: www.cegid.com ; http://jobs.cegid.com/
Follow Cegid on social media
https://www.facebook.com/CegidGroup/
https://twitter.com/CegidGroup
https://www.youtube.com/user/CegidOfficiel
https://www.linkedin.com/company/cegid
About Silver Lake
Silver Lake is a global technology investment firm, with more than $83 billion in combined assets under management and committed capital and a team of professionals based in North America, Europe, and Asia. Silver Lake's portfolio companies collectively generate more than $196 billion of revenue annually and employ more than 448,000 people globally. For more information about Silver Lake and its portfolio, please visit www.silverlake.com .
About KKR
KKR is a leading global investment firm that offers alternative asset management and capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of The Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at kkr.com and on Twitter @KKR_Co.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602006160/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom